Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 59Neoplasm Metastasis 24Stomach Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Neoplasms 8Brain Neoplasms 7Triple Negative Breast Neoplasms 5Adenocarcinoma 5Recurrence 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Esophageal Neoplasms 3Endometrial Neoplasms 3Advanced Solid Tumor 3Salivary Gland Neoplasms 2Meningeal Carcinomatosis 2HER2-positive Breast Cancer 2Colonic Neoplasms 2Breast Cancer With Brain Metastasis 2Advanced Breast Cancer 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Solid Cancer 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1fludarabine 1durvalumab 1cabazitaxel 1XRP6258 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Solid Cancer × trastuzumab deruxtecan × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡